Meeting Banner
Abstract #3640

Triethylenetetramine Treatment in Diabetic Heart Failure: An Animal Trial

Jun Lu1,2, Beau Pontre3, Stephen Pickup4, Bernard SY Choong1, Mingming Li1, Hong Xu5, Anthony RJ Phillips1, Garth JS Cooper6, Alistair A. Young7

1School of Biological Sciences, University of Auckland, Auckland, New Zealand; 2NCIECP, Auckland University of Technology, Auckland, New Zealand; 3Centre for Advance MRI, University of Auckland, Auckland, New Zealand; 4Department of Radiology, University of Pennsylvania, Philadelphia, PA, United States; 5Chemistry & Chemical Engineering, Shenzhen University, Shenzhen, Guangdong, China; 6Department of Pharmacology, Oxford University, Oxford, United Kingdom; 7Department of Physiology, University of Auckland, Auckland, New Zealand

End stage diabetes is often associated with heart failure, which is the leading cause of death. We are the first to investigate the heart function in STZ-induced diabetic rats longitudinally with and without triethylenetetramine (TETA) treatment using High Field MRI. Gradient echo cine method was used to determine cardiac function. We found that the cardiac ejection fraction decreased with prolonged diabetic status and oral TETA treatment improves ejection fraction in diabetic rats. The results suggest that TETA treatment is beneficial to diabetic heart failure and warrant further clinical investigation.